Intec Pharma Ltd TEL AVIV STOCK EXCHANGE

Equities

NTEC

IL0011177958

Delayed TEL AVIV STOCK EXCHANGE Other stock markets			5-day change	1st Jan Change
- ^ILa	-.--%		-0.67%	-16.62%

Mar. 14	Top Premarket Gainers	MT
Mar. 13	Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Intec Pharma : prices stock offering at $4.70; shares up 14%

August 16, 2017 at 10:37 am EDT

Intec Pharma (NTEC+13.9%) prices its public offering of 10.6M ordinary shares at $4.70 per share yielding gross proceeds of almost $50M. Underwriters over-allotment is an additional 1.6M shares. Closing date is August 21.
More news on: Intec Pharma, Healthcare stocks news, Stocks on the move,
Read more ...

Intec Pharma Ltd. published this content on 16 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 August 2017 14:36:06 UTC.

Original documenthttp://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=5419020098367698&topic=NTEC&symbology=null&cp=null&webmasterId=101803

Public permalinkhttp://www.publicnow.com/view/B831517D20C5E5CD71A51603345C741AA6728A72

Latest news about Intec Pharma Ltd

Top Premarket Gainers	Mar. 14	MT
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Top Midday Gainers	Mar. 04	MT
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial	Mar. 04	CI
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	Feb. 08	CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	Nov. 06	CI
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	23-10-31	CI
Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20	23-09-19	CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20	23-08-10	CI
Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023	23-08-08	CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
INDAPTUS THERAPEUTICS SHARES UP 11.4% AFTER POSITIVE PRE-CLINIC…	23-04-19	RE
Indaptus Therapeutics, Inc. Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at American Association for Cancer Research Conference 2023	23-04-19	CI
Indaptus Therapeutics, Inc. Announces Executive Changes	23-03-23	CI
HC Wainwright Adjusts Price Target on Indaptus Therapeutics to $12 From $15, Maintains Buy Rating	23-03-20	MT
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Indaptus Therapeutics, Inc. Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors	23-03-13	CI
Indaptus Therapeutics, Inc. Doses First Subject in Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors	23-03-07	CI
Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors	23-02-14	CI
HC Wainwright Reiterates Indaptus Therapeutics at Buy With $15 Price Target	23-02-08	MT
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors	23-02-07	CI
Indaptus Therapeutics, Inc. announced that it expects to receive $20 million in funding from Lincoln Park Capital, LLC	22-12-21	CI

Chart Intec Pharma Ltd

Duration

Period

More charts

Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson's disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

Sector

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company